Published July 1990 | Version v1
Journal article

The selection of patients for accelerated radiotherapy on the basis of tumor growth kinetics and intrinsic radiosensitivity

  • 1. Anderson (M.D.) Hospital and Tumor Inst., Houston, TX (USA)

Description

Mathematical modelling was used to reach qualitative conclusions concerning the relative rate of local tumor control that might be achieved by using accelerated fractionation to treat only the patients with the most rapidly growing rumors, compared with the control rated that could be expected from either conventional or accelerated radiotherapy alone. The results suggest that concomitant boost therapy is equally or more effective than conventional dose fractionation for all tumors, regardless of their growth kinetics. For tumors with very short clonogen doubling times, CHART (continuous hyperfractionated accelerated radiotherapy) may be even more effective than concomitant boost treatment, but CHART is less effective than conventional or concomitant boost therapy for tumors with longer clonogen doubling times. Thus, there is a rationale for using a predictive assay of tumor clonogen doubling times to identify the patients who should be treated with CHART. However, improvements in local tumor control resulting from concomitant boost treatment or the selective use of CHART are not likely to be apparent in the population as a whole, because the overall control rated are largely determined by refractory tumors having little chance of control with any of the treatments and by higher responsive tumors that are likely to be controlled regardless of the treatment choice. Differences in control rated with different treatment strategies are most apparent in the stochastic fraction of the population, which excludes those patients for whom there is either very little change (e.g. < 1%) or a very high change (e.g. > 99%) of achieving local control with both treatments. The stochastic fraction can be approximated by excluding those patients with the most radioresistant and the most radiosensitive tumors, since intrinsic tumor radiosensitivity appears to be the single most important factor determining treatment outcome. (author). 32 refs.; 4 figs.; 5 tabs

Additional details

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
18
Journal Issue
3
Series
Radiother. Oncol.
Journal Page Range
197-211
ISSN
0167-8140
CODEN
RAOND

INIS

Country of Publication
Ireland
Country of Input or Organization
Netherlands
INIS RN
22009361
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
FORECASTING; FRACTIONATED IRRADIATION; GROWTH; NEOPLASMS; RADIOSENSITIVITY; RADIOTHERAPY; SIMULATION
Descriptors DEC
DISEASES; IRRADIATION; MEDICINE; THERAPY